SYGNIS Pharma / SYGNIS granted US patent for QUALIPHI(R), the Next
Generation DNA amplification tool . Processed and transmitted by Thomson
Reuters ONE. The issuer is solely responsible for the content of this
New patent opens SYGNIS and QUALIPHI(R) in a leading position in a EUR70
million global market.
-- QUALIPHI(R) is a DNA polymerase which has demonstrated the potential to
improve complete DNA amplification from minimal concentrations
-- Polymerase proteins are essential in the research and analysis or
modification of DNA
-- QUALIPHI(R) reduces reaction time to 2 hours
-- Currently, the global DNA amplification market is estimated at EUR70
million, with the US the largest market.
Madrid/Heidelberg, 23 April 2013 - The biotech company SYGNIS Pharma AG
(Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) has been granted a
patent by the USPTO (US patent and Trademark office) for its flagship
product, QUALIPHI(R) the polymerase for complete DNA amplification.
Polymerase proteins are the main tool for amplifying long DNA fragments
and whole genomes, and are a basic need for research involving the
analysis and modification of DNA.
QUALIPHI(R) is an upgraded version of the Phi 29 DNA polymerase used in
isothermal amplification which provides enhanced properties compared to
similar polymerase proteins on the market. Being less time-consuming and
having highly superior performance characteristics, the method developed
by SYGNIS enables DNA amplification from concentrations as low as those
found in a single cell. This is extremely useful in cancer research, and
many other applications.
"Certainly, the need for amplification of nucleic acids from minimal
concentrations as present in single cell applications will be a critical
issue in the coming era of personalised medicine and NGS. We expect
QUALIPHI(R) to become an essential tool for the DNA amplification needed
in these markets", said SYGNIS' CEO, Pilar de la Huerta.
With the significant growth in the field of DNA amplifications used in
sequencing and personalised medicine, the market of whole genome
amplification with polymerase proteins is expected to grow at over 20%
per annum over the next few years. Current estimates indicate that the
size of the global isothermal DNA market alone is approximately EUR70
million, with the US as the leading market for QUALIPHI(R) .
In 2012, SYGNIS granted an exclusive global licence to QIAGEN, including
sublicensing rights, for the commercialization of QUALIPHI(R) in the DNA
amplification market. QIAGEN is a global leader in sample and assay
technologies in research and molecular diagnostics.
About SYGNIS Pharma AG: www.sygnis.de
After the merger in 2012 between X-Pol Biotech, specialising in DNA
amplification and sequencing, and SYGNIS Pharma AG, listed in the German
Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03),
SYGNIS' new mission is to develop and distribute technologies and
products from X-Pol, which has a commercial product in the DNA
amplification segment, QUALIPHI(R) , and is currently developing other
products in the field of Next Generation Sequencing.
For further information:
Pilar de la Huerta
CEO/CFO of SYGNIS Pharma AG
,+34 902 02 69 31 / 609 47 29 34 / 654 41 01 11
# # # Disclaimer:
Some statements included in this press release, relating neither to
proven financial results nor to other historical data, should be viewed
as forward-looking, i.e. not definitive. Such statements are mainly
predictions of future results, trends, plans or goals. These statements
should not be considered to be total guarantees since given their very
nature, they are subject to known and unknown risks, as well as to
aspects beyond human control, and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light of
new information or future results or for any other reason. # # #
Press release (PDF): http://hugin.info/150277/R/1695126/557691.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the
information contained therein.
Source: SYGNIS Pharma via Thomson Reuters ONE
--- End of Message ---
Im Neuenheimer Feld 515 Heidelberg Germany
(END) Dow Jones Newswires
April 23, 2013 02:31 ET (06:31 GMT)- - 02 31 AM EDT 04-23-13